C12Y 304/21038
Coagulation factor xiia
Official title: Coagulation factor XIIa (3.4.21.38)
C12Y304/21038 (Coagulation factor xiia) appears on 10 US grants and 21 published applications in this corpus.
Search patents in C12Y- Granted patents
- 10
- Published applications
- 21
- Assignees
- 11
- Inventors
- 43
- Latest grant
- 14 Oct 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 2 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 2 |
| 2015 | 0 | 1 |
| 2016 | 1 | 3 |
| 2017 | 0 | 2 |
| 2018 | 2 | 1 |
| 2019 | 2 | 3 |
| 2020 | 0 | 2 |
| 2021 | 0 | 0 |
| 2022 | 2 | 1 |
| 2023 | 1 | 0 |
| 2024 | 0 | 1 |
| 2025 | 1 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Assays for determining plasma kallikrein system biomarkers14 Oct 2025US 12,442,824 B2Takeda Pharmaceutical Company Limited
- Blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings5 Sep 2023US 11,744,880 B2CSL Behring GmbH
- Assays for determining plasma kallikrein system biomarkers28 Jun 2022US 11,372,002 B2Takeda Pharmaceutical Company Limited
- Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies31 May 2022US 11,345,759 B2CSL Behring GmbH
- Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies24 Dec 2019US 10,513,560 B2CSL Behring GmbH
- Urokinase-type plasminogen activator receptor binding peptides and methods of use19 Jun 2025US 2025/0197838 A1Case Western Reserve University
- Thrombolytic microspheres to dissolve vaso-occlusive clots12 Dec 2024US 2024/0408017 A1
- Assays for determining plasma kallikrein system biomarkers15 Sep 2022US 2022/0291232 A1Takeda Pharmaceutical Company Limited
- Methods to reduce adverse events caused by pharmaceutical preparations comprising plasma derived proteins29 Oct 2020US 2020/0338123 A1CSL Behring GmbH
- Methods of administering inhibitory anti-factor xii/xiia monoclonal antibodies27 Feb 2020US 2020/0062863 A1CSL Behring GmbH
Most cited
By later US patents
- Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same23US 4,963,657 ATemple University of the Commonwealth System of Higher Education · 1990
- Assays for determining plasma kallikrein system biomarkers6US 11,372,002 B2Takeda Pharmaceutical Company Limited · 2022
- Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies6US 9,856,326 B2CSL Behring GmbH · 2018
- Inhibitory anti-factor XII/XIIA monoclonal antibodies and their uses5US 9,518,127 B2CSL Behring GmbH · 2016
- Nucleic acids encoding inhibitory anti-factor XII/XIIa monoclonal antibodies4US 9,856,325 B2CSL Behring GmbH · 2018